Wockhardt Limited
WOCKPHARMA
Pozycja w akcjach
#4507
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Cena akcji
$21.02
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$3.42B
Zmiana (1 dzień)
-2.48%
Zmiana (1 rok)
37.94%
Kraj
IN
Handel Wockhardt Limited (WOCKPHARMA)
Kategoria
Healthcare
EPS dla Wockhardt Limited (WOCKPHARMA)
EPS na dzień June 2026 TTM: $0.28
Według najnowszych raportów finansowych i ceny akcji firmy Wockhardt Limited, obecny EPS (TTM) wynosi $0.28. Na koniec roku 2024 firma miała EPS w wysokości $-0.39, spadek w porównaniu do do EPS z roku 2023, który wynosił $-0.47.
Historia EPS dla Wockhardt Limited od 2004 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $0.28 | -794.25% |
| 2025 | $-0.04 | -90.88% |
| 2024 | $-0.39 | -18.45% |
| 2023 | $-0.47 | 77.08% |
| 2022 | $-0.27 | -21.59% |
| 2021 | $-0.34 | 73.20% |
| 2020 | $-0.20 | -47.92% |
| 2019 | $-0.38 | -55.39% |
| 2018 | $-0.84 | 209.37% |
| 2017 | $-0.27 | -179.67% |
| 2016 | $0.34 | -41.89% |
| 2015 | $0.59 | -53.86% |
| 2014 | $1.28 | -51.83% |
| 2013 | $2.65 | 366.49% |
| 2012 | $0.57 | 232.75% |
| 2011 | $0.17 | -109.11% |
| 2010 | $-1.88 | 678.46% |
| 2008 | $-0.24 | -129.20% |
| 2007 | $0.83 | 80.04% |
| 2006 | $0.46 | -4.80% |
| 2005 | $0.48 | 16.08% |
| 2004 | $0.41 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $2.41 | 767.84% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -93.23% |
HK
|
